This specificity is primarily attributed to the conformational changes in EGFR resulting from overexpression in tumor cells, which expose the binding site of mAb806; conversely, the normal conformation of EGFR in normal cells impedes this binding [94].Through this strategy, EGFR806-CAR T cells exhibited significant anti-tumor activity in mouse models [95]. This evidence concerns the gene EGFR and neoplasm.